Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8H8-SDIE
- Development stage
- Preclinical
- Lead developer
- Eberhard Karls Universität Tübingen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
8H8-SDIE is an Fc-optimized monoclonal antibody targeting CD276 (B7-H3), an immune checkpoint protein overexpressed in various solid and hematological malignancies. Developed by the University of Tübingen, the antibody is an engineered variant of the 8H8 clone, incorporating S239D and I332E (SDIE) mutations in the Fc region to significantly enhance its binding affinity to the CD16 (FcγRIIIa) receptor on natural killer (NK) cells. This modification promotes potent antibody-dependent cellular cytotoxicity (ADCC) against tumor cells. The drug is currently in preclinical development for indications including colorectal cancer, non-small cell lung cancer, ovarian cancer, and acute myeloid leukemia.
- Other names
- Fc-optimized anti-CD276 monoclonal antibodyFc-optimized 8H8Fc-optimized8H8Fc-optimized-8H8
02
Targets
FCGR3B (Fc gamma receptor III)B7-H3
Beyond the preview
Go deeper on 8H8-SDIE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 8H8-SDIE.